Mark S Segal, MD, PhD - Research

Research at a glance

Top areas of exploration

Cells, Cultured , 19 publications
Biomarkers , 17 publications
Kidney Failure, Chronic , 16 publications
Hypertension , 16 publications

Research activity

161 publications

10,466 citations

Why is this important?

Active clinical trials

HyperQure RDN System

HQ-HTN-G01 is a prospective, multicenter, single arm, open label, early feasibility study to evaluate initial safety and device design concept of "HyperQureTM RDN System", laparoscopic renal denervation therapy, in patients with resistant鈥�

Investigator: Mark S Segal
Status: Accepting Candidates
Ages: 22 Years - 80 Years
Sexes: All

EASi-KIDNEY

Investigator: Mark S Segal
Status: Accepting Candidates

REGEN-006

The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and delivered percutaneously into biopsied and non-biopsied contralateral kidneys in participants with鈥�

Investigator: Mark S Segal
Status: Accepting Candidates
Ages: 30 Years - 80 Years
Sexes: All

My publications

161 publications

2008

Carbon monoxide and nitric oxide mediate cytoskeletal reorganization in microvascular cells via vasodilator-stimulated phosphoprotein phosphorylation: evidence for blunted responsiveness in diabetes.

Diabetes..

鈥�

2008

How safe is fructose for persons with or without diabetes?

The American journal of clinical nutrition

2008

Long-term engraftment of bone marrow-derived cells in the intimal hyperplasia lesion of autologous vein grafts.

The American journal of pathology

鈥�

2008

Tacrolimus rescue therapy in resistant or relapsing cases of primary glomerulonephritis.

Journal of nephrology

2007

A breakthrough in diabetic nephropathy: the role of endothelial dysfunction.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

网红黑料